Aelis Farma SAS: A Glimpse into the French Pharmaceutical Company

Aelis Farma SAS, a prominent player in the health care sector, is a French pharmaceutical company headquartered in Paris. The company is listed on the NYSE Euronext Paris stock exchange, reflecting its significant presence in the pharmaceutical industry.

As of May 22, 2025, Aelis Farma SAS’s close price stood at 1.205 EUR. This figure is a notable increase from its 52-week low of 1 EUR, recorded on April 6, 2025. However, it remains far below the 52-week high of 13.2 EUR, achieved on June 9, 2024. These fluctuations highlight the volatility in the company’s stock performance over the past year.

The market capitalization of Aelis Farma SAS is currently valued at 134,400,000 EUR. Despite its substantial market presence, the company’s price-to-earnings ratio is -2.17, indicating that it is not currently generating profits. This negative ratio may be a point of concern for investors looking for immediate returns.

Aelis Farma SAS continues to operate within the dynamic health care sector, focusing on the development and commercialization of innovative pharmaceutical solutions. The company’s strategic initiatives and research endeavors are crucial as it navigates the challenges and opportunities within the industry.

As Aelis Farma SAS progresses, stakeholders will be closely monitoring its financial performance and strategic developments to gauge its future trajectory in the competitive pharmaceutical landscape.